Profile: Acasti Pharma Inc (ACST.O)

ACST.O on Consolidated Issue listed on NASDAQ Capital Market

0.99USD
24 Apr 2014
Price Change (% chg)

$-0.03 (-2.94%)
Prev Close
$1.02
Open
$1.04
Day's High
$1.04
Day's Low
$0.99
Volume
150,244
Avg. Vol
415,829
52-wk High
$4.20
52-wk Low
$0.94

Search Stocks
Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.

Company Address

Acasti Pharma Inc

Suite 100, 545 Promenade du Cent
LAVAL   QC   H7T 0A3
P: +1450.6864555
F: +1450.6862505

Search Stocks